AlphAIalphai — Financial news for AI agents
finance.yahoo.comAUG 96 min read$RVTY

Revvity Q2 Earnings Call Highlights

Revvity (RVTY) reported Q2 results on an earnings call, with Diagnostics revenue of $352M up 12% reported and 11% organic. Life Sciences revenue was $359M, down 2% reported and 3% organic, driven by a ~20% Signals software decline. For 2026, it raised pro forma organic growth to 4%-5% and guided revenue $2.83B-$2.86B, adjusted EPS $5.30-$5.40. It expects Q3 revenue $685M-$700M and organic growth 4%-6%.

Original reporting
finance.yahoo.com
Published Aug 9, 2026, 4:03 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 9, 2026, 10:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Revvity Q2 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RVTYBullishMed
01

Why it matters

For RVTY, the key tradable items are the raised full-year pro forma organic growth outlook, updated revenue/margin/EPS ranges, and the expectation for instruments to deliver positive mid-single-digit growth with reagents accelerating later in the year. Offsetting factors include a ~20% year-over-year Signals software decline and Life Sciences revenue down 2% reported and 3% organic.

02

Market read

Raised guidance and a stronger backlog narrative support RVTY’s forward growth profile, while software and Life Sciences declines highlight near-term execution and comparison risks.

03

What to watch

The guidance shift is partly driven by instrument shipment timing and contract renewal assumptions for Signals; traders should watch whether order velocity sustains into realized revenue.

Relevance 8/10Novelty 8/10Timing: post-market/early pre-open read-through from the Q2 earnings call

Background

The piece summarizes Revvity’s Q2 earnings call, including segment results, leverage/financing details, and updated 2026 and Q3 guidance.

Company-level read

Ticker impact

$RVTYBullishMedium confidence
Context

Revvity raised 2026 pro forma organic growth to 4% to 5% and guided Q3 revenue and margins after Q2 segment performance and backlog strength.

Expected impact

Bias toward upward estimate revisions and supportive near-term trading, with volatility around Signals and Life Sciences order timing.

Evidence & confidence

The article includes explicit updated full-year and Q3 targets, segment revenue trends, and a backlog/instrument demand narrative that can drive revisions, but it also flags a ~20% Signals software decline and Life Sciences revenue contraction.

Market effects

Sector

Signals AI and high-content screening instrument demand tied to AI drug discovery may reinforce sentiment for life-science tools and workflow software adoption.

Regional

Diagnostics growth outside China remained resilient despite latent TB testing pressure, suggesting less China concentration risk than peers.

Global

AI-driven lab workflows and instrument backlog dynamics can influence broader expectations for biotech tools demand cycles.

Counterpoint

What could challenge this read

The raised instrument growth outlook may be offset by continued software weakness and difficult comparisons, so upside could fade if backlog converts slower than expected.

Key entities

  • public_company
    Revvity, Inc.

    Life-sciences and diagnostics tools and software provider; subject of the earnings call highlights and guidance updates.

  • partner_or_customer
    Genomics England

    Referenced as a contributor to Reproductive Health comparisons and expected moderation in H2.

  • technology_partner
    Anthropic

    Referenced via an announced connector for Signals AI to use customer data with Claude and Claude Science.

Read at source← All news

Related articles

SEP 1
$RVTYMed

RBC Capital initiates Revvity stock with Sector Perform rating

RBC Capital initiated coverage on Revvity Inc. (NYSE:RVTY) with a Sector Perform rating and a $135 price target. The stock trades near its 52-week high after a 31% surge over six months. RBC cited durable franchises but noted structural challenges to growth. Revvity's P/E ratio is 61, and it is considered overvalued. The company reported Q2 earnings and revenue above expectations, driven by organic growth and AI demand. Stifel raised its price target to $110 but maintained a Hold rating.

investing.com2 min
AUG 31
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min
AUG 11
$RVTYHighAI 9/10

Revvity (RVTY) Q2 2026 Earnings Call Transcript

Revvity (RVTY) reported Q2 2026 pro forma revenue of $711 million, up 3% organically, and pro forma adjusted EPS of $1.41. Diagnostics revenue rose 11% organically, while Signals software declined 20% organically. Free cash flow was $184 million. Full-year organic growth guidance was raised to 4% to 5% and adjusted EPS to $5.30 to $5.40.

fool.com7 min
AUG 6
$RVTYMed

Revvity, Inc. Q2 2026 Earnings Call Summary

Revvity, Inc. reported Q2 2026 results, citing improving pharma and biotech spending and higher orders tied to AI-driven drug discovery. Management said Opera Phenix OptIQ demand outpaces capacity, raised full-year organic growth guidance to 4% to 5%, and expects Signals software double-digit growth in H2. It signed an agreement to divest China immunodiagnostics and targets gross leverage below 3x by year-end.

yahoo.com6 min
AUG 5
$RVTYMedAI 8/10

Why Revvity (RVTY) Stock Is Up Today

Revvity (NYSE: RVTY) shares rose about 3% after the company reported Q2 2026 adjusted EPS of $1.41 versus $1.21 expected, and revenue of $729.68 million versus $703.39 million. Revvity lifted full-year guidance to 4% to 5% organic growth and EPS of $5.30 to $5.40. Stifel raised its target to $110 and Bernstein to $120.

financialcontent.com4 min
AUG 4
$RVTYMedAI 9/10

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity (RVTY) reported Q2 2026 adjusted EPS of $1.41, up 19.5% and above the $1.23 Zacks estimate. Revenue rose 1.3% to $729.7 million, beating $704.5 million. Pro forma revenues were $711.1 million. Diagnostics grew; Life Sciences declined. Revvity raised 2026 pro forma revenue to $2.83-$2.86B and EPS to $5.30-$5.40 and agreed to divest China Immunodiagnostics.

tradingview.com6 min